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bjectives We angioscopically compared paclitaxel-eluting stents (PES) and sirolimus-eluting stents
SES) to explore differences in arterial healing.
ackground Drug-eluting stents may demonstrate different arterial healing processes.
ethods Angioscopy was performed 9  2 months after 30 PES and 36 SES were implanted ini-
ially in the native coronary artery. Heterogeneity of the neointimal coverage (NIC) as well as the
ominant grade was examined. Neointimal coverage was deﬁned as follows: grade 0  fully visible
truts; grade 1  struts bulged into the lumen, but covered; grade 2  embedded, but translucent
truts; grade 3  invisible struts. Heterogeneity was judged when the NIC grade variation 1.
hrombi and yellow plaques (YP) were also explored.
esults In-stent late loss (0.44  0.44 mm vs. 0.13  0.33 mm; p  0.0001) and dominant NIC
rade (1.8  1.1 vs. 1.3  0.7; p  0.02) were greater in PES than in SES. Of PES, 48% showed the
eterogeneity of 1 grade; 26% showed that of 2 grades. Of SES, 53% showed homogeneous cover-
ge; the remaining SES showed the heterogeneity of 1 grade; and 72% showed dominant grade 1.
hrombi were more common in PES than in SES (43% vs. 19%; p  0.04). Both stents commonly
evealed YP (83% vs. 78%; p  0.76).
onclusions NIC was more heterogeneous in PES, associated with a higher incidence of thrombi.
omogeneous NIC may be an important factor for competent arterial healing. (J Am Coll Cardiol
ntv 2009;2:453–8) © 2009 by the American College of Cardiology Foundation
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454rug-eluting stents (DES) have significantly reduced reste-
osis through an inhibitory effect on neointimal hyperplasia
1,2). Currently, concerns have been raised about late stent
hrombosis (LST) and very LST after DES implantation as
negative aspect of the strong inhibition of neointimal
roliferation (3–6). Pathological studies showed that in-
omplete neointimal coverage (NIC) following stenting
ontributes to LST (7,8). Using angioscopy, we have pre-
iously reported (9) that the NIC was not complete even 2
ears after sirolimus-eluting stent (SES) implantation, as-
ociated with yellow plaques (YP) and subclinical thrombi,
hereas bare-metal stents (BMS) showed complete NIC.
he paclitaxel-eluting stent (PES) is also a first-generation
ES that has been widely used in the real world. Although
larifying the differences in arterial healing between PES
nd SES is important to discuss clinical managements
ollowing DES, arterial healing following PES has not been
ngioscopically defined. Hence, using angioscopy, we
ought to investigate the lumen/stent surfaces following
ES and SES implantation for new lesions of the native
coronary arteries.
Methods
Patients. This study was a non-
randomized, historical control
study that included 40 patients
with stable angina pectoris in
whom 66 DES were implanted
(35 men, age 35 to 85 years).
The patients agreed to receive
follow-up angioscopy as well as
angiography 8 months after
stenting. Among them, 19 pa-
ients were treated with SES alone (27 stents) (Cypher,
ordis, Miami Lakes, Florida); 14 patients were treated
ith PES alone (18 stents) (TAXUS Express 2, Boston
cientific, Natick, Massachusetts); 7 patients were treated
ith both SES (9 stents) and PES (12 stents). All patients
eceived ticlopidine (200 mg/day) in addition to aspirin (100
o 200 mg/day) during the follow-up, except for 2 patients.
either a glycoprotein IIb/IIIa inhibitor nor clopidogrel
as used because they were not approved for stable angina
ectoris in Japan.
ngiographic and angioscopic follow-up. Coronary angiog-
aphy was performed after the administration of heparin
5,000 IU) into the femoral artery via the inserted sheath,
nd isosorbide dinitrate (2.5 mg) into the coronary artery.
ubsequently, angioscopy was performed using Vecmova
EO (FiberTech, Tokyo, Japan). The detailed specifica-
ions and the procedures of the angioscope have been
escribed elsewhere (10,11). Briefly, the optical fiber was
laced at the distal segment of the coronary artery and was
bbreviations
nd Acronyms
MS  bare-metal stent(s)
ES  drug-eluting stent(s)
L  late loss
ST  late stent thrombosis
IC  neointimal coverage
ES  paclitaxel-eluting
tent(s)
ES  sirolimus-eluting
tent(s)
P  yellow plaquesanually pulled back from the distal edge of the stent to the iroximal edge under careful angioscopic and angiographic
uidance. Angioscopic images consisted of 3,000 pixels with
ull color and were stored on digital videotapes for off-line
nalysis.
uantitative coronary angiography. Coronary angiography
as performed in at least 10 projections, and the view
howing the most severe stenosis was selected for quantita-
ive coronary angiography (12). Quantitative coronary an-
iography was performed using the CASS system (Pie
edical BV, Maastricht, the Netherlands) before stenting,
mmediately after stenting, and also at follow-up with the
ame angle of projection.
ngioscopic analysis. Angioscopic images were analyzed as
ollows: 1) the dominant degree of NIC over the stent; 2)
eterogeneity of NIC; 3) existence of thrombus; and 4)
xistence of YP underneath the stent. Neointimal coverage
ver the stent was classified into 4 grades as previously
escribed (9,13,14). In brief, grade 0  stent struts were
ully visible, similar to immediately after implantation; grade
 stent struts bulged into the lumen and, although
overed, were still transparently visible; grade 2  stent
truts were embedded by the neointima, but were translu-
ently seen; grade 3  stent struts were fully embedded and
ere invisible by angioscopy. Neointimal coverage was
valuated in the entire stented segments, and if different
IC grades of more than or equal to 1 grade were present,
he NIC was judged as heterogeneous. Struts that crossed
he side branch were excluded from grading because they all
howed grade 0 regardless of the stent types. The stent
dges were also excluded from the heterogeneity analysis.
tent overlapped segments were also evaluated separately.
hrombus was defined based on the criteria adopted by the
uropean Working Group on Coronary Angioscopy (15).
he angioscopic definition of YP was adopted from the
arlier reports (10,11,16), and the existence of YP under-
eath the stent was evaluated.
tatistical analysis. All results are expressed as mean  SD
median] unless otherwise stated. Comparisons between the
groups were done with the Wilcoxon rank sum test.
ategorical variables were analyzed with Fisher exact test
or 2  2 comparisons; for more than 2  2 comparisons,
he chi-square test was used. Analyses for quantitative
oronary angiography and angioscopic findings were per-
ormed per stent, but not per patient. Statistical significance
as defined as p  0.05. All calculations were performed
sing JMP 7.0.1 (SAS Institute, Cary, North Carolina).
esults
atients. Patient, lesion, and procedure characteristics were
qually distributed between the PES and the SES groups
Tables 1 and 2), except that the duration from the stent
mplantation to the follow-up angiography and angioscopy
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455ere slightly longer in SES (9.2  1.5 [9.2] months) than
n PES (8.4  1.7 [8.0] months; p  0.01).
uantitative coronary angiography. Quantitative coronary
ngiographic findings in the PES and the SES groups are
hown in Table 2. Although there were no statistical
ifferences between them, baseline lesion length tended to
e longer in SES than in PES; reference diameter tended to
e larger in SES than in PES. Although a post-interventional
ngiogram as well as procedural characteristics were similar
etween PES and SES, in-stent late loss (LL) from the
ost-intervention to follow-up was smaller in SES (0.13 
Table 1. Patient and Lesion Characteristics
PES
No. of patients 21
Age, yrs 67  9.7 [66]
Male 18 (86)
Coronary risk factors
Hypertension 14 (67)
Dyslipidemia 14 (67)
Diabetes mellitus 9 (43)
Smoking 13 (62)
Multivessel disease 18 (86)
History of previous MI 6 (29)
No. of stents 30
LAD/LCX/RCA 11 (37)/4 (13)/15 (50
Type B2/C lesions* 23 (77)
Data are presented as mean SD [median] or n (%). *Based on Ameri
LAD  left anterior descending artery; LCX  left circumflex artery
coronary artery; SES sirolimus-eluting stent(s).
Table 2. Procedural Characteristics and Serial Chang
PE
No. of stents 3
Stent diameter, mm 3.00 0.
Stent length, mm 21.8 7.
Stent-to-artery ratio 1.11 0.
Quantitative coronary angiography
Pre-intervention
Lesion length, mm 15.5 6.
Reference diameter, mm 2.73 0.
Minimal lumen diameter, mm 0.69 0.
Diameter stenosis, % 75.5 10
Post-intervention
Minimal lumen diameter, mm 2.67 0.
Diameter stenosis, % 13.6 6.
Follow-up
Minimal lumen diameter, mm 2.23 0.
Diameter stenosis, % 22.5 15
In-stent late loss, mm 0.44 0.
Follow-up duration, months 8.4 1.
Data are presented as mean SD [median] or n (%).Abbreviations as in Table 1..33 [0.08] mm) than in PES (0.44  0.44 [0.32] mm; p 
.0001), and resulted in the smaller minimal lumen diameter
nd a larger percent diameter stenosis at follow-up in PES than
n SES. Three PES and a SES showed in-stent restenosis
50% of diameter stenosis) at follow-up angiography.
mong them, all the PES received target lesion revasculariza-
ion, but the SES did not.
ngioscopic ﬁndings. Dominant NIC grade was signifi-
antly different between PES and SES (Fig. 1). The average
rade was greater in PES (1.8 1.1 [2] grades) than in SES
1.3  0.7 [1] grades; p  0.02). Although the majority of
SES p Value
26
67  9.6 [68] 0.73
21 (81) 0.72
20 (77) 0.52
21 (81) 0.33
10 (38) 0.77
13 (50) 0.56
25 (96) 0.31
8 (31) 1.00
36
18 (50)/4 (11)/14 (39) 0.55
31 (86) 0.36
lege of Cardiology/American Heart Association classification.
myocardial infarction; PES  paclitaxel-eluting stent(s); RCA  right
Quantitative Coronary Angiography Data
SES p Value
36
0] 3.10 0.35 [3.00] 0.25
0] 24.7 4.63 [23.0] 0.22
9] 1.08 0.14 [1.04] 0.15
3] 18.8 6.54 [20] 0.053
7] 2.91 0.41 [3.00] 0.07
4] 0.61 0.34 [0.68] 0.31
5] 78.5 11.8 [76.5] 0.22
8] 2.76 0.38 [2.82] 0.23
0] 11.8 5.78 [12.0] 0.25
6] 2.63 0.43 [2.72] 0.0009
5] 16.0 10.7 [15.0] 0.046
2] 0.13 0.33 [0.08] 0.0001
9.2 1.5 [9.2] 0.01)
can Col
; MI es in
S
0
37 [3.0
80 [24.
14 [1.0
09 [15.
52 [2.6
35 [0.7
.2 [72.
40 [2.6
92 [15.
53 [2.2
.7 [20.
44 [0.3
7 [8.0]
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456ES showed grade 1 (n  26, 72%), PES showed dispersed
IC grades. Within the stents, NIC was more heteroge-
eous in PES than in SES (Fig. 2). Of SES, 47% had
eterogeneous NIC, but all of them showed heterogeneity
f 1 grade. In contrast, PES showed a higher incidence of
eterogeneity (74%); the heterogeneity of 1 grade was
etected in 48%; the heterogeneity of 2 grades was detected
n 26%, which was not observed in SES. A representative
ase is shown in Figure 3.
All the thrombi detected were mural and subclinical and
ere more frequently observed in PES (43%) than in SES
19%; p  0.04). One of these thrombi was white, which
Figure 1. Distribution of Dominant Neointimal Coverage Grades at
Follow-Up in PES and in SES
Although 72% of sirolimus-eluting stents (SES) showed the dominant
neointimal coverage of grade 1, paclitaxel-eluting stents (PES) showed
widely dispersed neointimal coverage. PES versus SES, p  0.0006 by
chi-square test.
Figure 2. Heterogeneity of NIC Grades in PES and in SES
Forty-seven percent of SES showed the heterogeneity of 1 grade. Fifty-
three percent demonstrated homogenous neointimal coverage (NIC). In
contrast, 74% of PES showed heterogeneous NIC: 48% showed the hetero-
geneity of 1 grade; 26% showed the heterogeneity of 2 grades, which was
not observed in SES. PES versus SES, p  0.002 by chi-square test. Abbrevi-s
ations as in Figure 1.as detected in a SES that showed NIC of grade 1. The
emaining 19 thrombi were red thrombi. All the thrombi
ere present at the site of grade 0/1. Yellow plaques were
imilarly common in PES (83%) and in SES (78%; p 
.76). Most of them were detected underneath the neoin-
ima of grades 0 to 2 (88%).
A total of 12 segments were overlapped: PES covering
ES (n  1); SES covering SES (n  4); PES covering
ES (n  3); SES covering PES (n  4). Five segments
ere overlapped with the same DES. The PES covering
ES showed grade 2, and the nonoverlapped segments
evealed grade 3. Three of the SES covering SES showed
rade 1 throughout the stent. The other SES covering SES
evealed grade 3, which was associated with moderate
tenosis (50% of diameter stenosis). The other 7 segments
ere overlapped with SES and PES, which in general
Figure 3. Coronary Angiograms and Angioscopic Images 8 Months After
the Tandem Implantation of SES and PES
Angiograms at follow-up revealed no restenosis at the segment of SES (3.5
 23 mm) and PES (3.5  24 mm) implanted in tandem. Angioscopic
images of SES showed homogeneous NIC of grade 1. In contrast, PES
showed the heterogeneity of 2 grades; the dominant degree of NIC was
grade 2 in PES; the distal segment showed NIC of grade 0, with mural red
thrombi adhered on the yellow plaques and the naked stent struts.
Dashed blue line  SES-implanted site; dashed red line  PES-implanted
site. GW  guide wire; other abbreviations as in Figures 1 and 2.howed low-grade coverage that was similar to the nonover-
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457apped segments, except for a SES covering PES, which
howed grade 3 with moderate stenosis: SES covering PES
howed grade 0 (n  2) to grade 1 (n  1); PES covering
ES showed grade 1 (n  2) to grade 2 (n  1). Exposed
truts were only seen in the segments of SES covering PES
n this limited observation.
iscussion
he present study compared the vascular lumen/stent sur-
aces in patients following PES implantation with those
ollowing SES using angioscopy. Late loss was slightly, but
tatistically greater in PES than in SES. Although 72% of
ES showed the dominant NIC of grade 1, PES showed
idely dispersed NIC grades. Within the stents, NIC was
ore heterogeneous in PES than in SES. Thrombi were
ore frequently observed in PES (43%) than in SES (19%,
 0.04). Yellow plaques were commonly detected both in
ES (83%) and in SES (78%, p  0.76).
Late losses in each group of this study were similar to
hose found in several other clinical studies for these stents
1,2,17). Similar to SES, PES is one of the first generation
ES to reduce LL and target lesion revascularization by
nhibiting neointimal hyperplasia. It has been pointed out,
owever, that incidence of LST may be higher following
ES or SES placements than following BMS placements
3–6). Since the beginning of the BMS era, pathological
tudies have indicated that incomplete NIC causes LST (7).
nother pathological study also suggested that incomplete
IC over SES and PES causes LST (8). In our previous
tudy, a zotarolimus-eluting stent (Endeavor, Medtronic,
inneapolis, Minnesota), which demonstrated greater LL
han SES, appeared to have angioscopically more competent
IC than SES (14). Although PES showed intermediate
L among these DES (17), PES revealed heterogeneous
IC, which did not cover the stent struts as well as the
nderlying YP completely. Both intra- and interstent het-
rogeneities of NIC grades were more significant in PES,
hile PES was associated with a higher frequency of
hrombi than SES. Several meta-analyses revealed the
igher incidence of LST in PES than in SES, whereas PES
ad higher LL than SES (18,19). The results of this study
ay explain the mechanism of the higher incidence of LST
n PES in spite of the greater LL in PES than in SES.
ngioscopically, thrombus adheres to the sites of incom-
lete NIC following DES placement (9,13).
In the present study, PES had a similar incidence of YP
s did SES. Using angioscopy, Miyamoto et al. (20)
emonstrated that intimal wall thickness and percent yellow
aturation correlated inversely in vitro; that is, angioscopic
olor reflected the thickness of the fibrous cap. A clinical
tudy using optical coherence tomography also demon-
trated the relationship between the fibrous cap thickness
nd the yellow saturation of YP in angioscopy (21). Yellow ilaque was reduced following BMS or zotarolimus-eluting
tent placement, possibly by covering the YP with the
eointimal development. Neointima covering the YP may
ave a “plaque-sealing effect” to stabilize plaques (9,11,14).
n fact, although the event rate following BMS implanta-
ion was higher in target lesions than in nontarget lesions
ue to restenosis in year 1, the target lesions (i.e., stented
egments) were clinically stable from year 2 through year 5
target lesion  1.7% vs. nontarget lesion  6.3%) (22).
his may be due to a lesion stabilization effect of the
eointima. Our previous angioscopic studies (9,14) sug-
ested that this plaque-sealing effect may not be expected in
ES implantation due to the lack of neointimal develop-
ent. Paclitaxel-eluting stents may also lack this protective
ealing effect because both SES and PES showed a high
ncidence of YP. Although PES had a higher incidence of
rade 3 than did SES, both without restenosis, the hetero-
eneity of NIC following PES hampered the YP sealing
ffect as observed in BMS or zotarolimus-eluting stents.
linical implications. The present study demonstrated het-
rogeneous NIC following PES, which resulted in the
igher incidence of thrombus adhesion as well as partially
ncomplete NIC. These angioscopic results endorse the
ecommendation of dual antiplatelet therapy for at least 1
ear for patients treated with DES including PES (23,24).
t is important to recognize from this study the homoge-
eous NIC following stenting may also be an indispensable
actor to developing next-generation stents.
tudy limitations. This study was a single center, nonran-
omized, historical control study with a small sample size.
he follow-up term in this study was slightly longer in SES
han in PES. However, NIC 3 months to 1 year after SES
mplantation was similar when serially compared using
ngioscopy (9). The follow-up term may be too short to
nderstand the chronological changes in arterial healing
ollowing PES. Long-term, serial angioscopic follow-up
tudy is necessary for this purpose. Although statistically
nsignificant, PES tended to have more restenosis (n  3)
han SES (n  1; p  0.3). This may bias the angioscopic
bservation. Nonetheless, this may also be clinically relevant
ecause meta-analyses including a large number of patients
ave indicated higher rates of restenosis and target lesion
evascularization rates in PES than in SES (18,19). Al-
hough 7 patients were treated with both PES and SES,
nalyses in the quantitative coronary angiography and an-
ioscopy were performed per stent without correction for
orrelated observations in the same patients.
onclusions
eointimal coverage grades were more heterogeneous in
ES than in SES and were associated with a higherncidence of thrombi in PES. Homogeneous NIC may be
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458n important factor for competent arterial healing following
ES.
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